Danny Vesprini
@dannyvesprini.bsky.social
RadOnc and Assoc Prof at Sunnybrook Health Sciences Centre, UofT. Prostate and breast cancer clinical trials, genetic biomarkers, active surveillance. Jack of all trades master of none. Husband, father, and part time wine snob
Reposted by Danny Vesprini
Excited to see the HERMES trial results in print www.sciencedirect.com/science/arti...
Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk
Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk
HERMES: Randomised trial of 2-fraction or 5-fraction MRI-guided adaptive prostate radiotherapy
To demonstrate safety and feasibility of 2-fraction stereotactic body radiotherapy (SBRT) for prostate cancer.This single centre, non-comparative, pha…
www.sciencedirect.com
May 23, 2025 at 6:48 AM
Excited to see the HERMES trial results in print www.sciencedirect.com/science/arti...
Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk
Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk
Reposted by Danny Vesprini
What could be better than 5 days in Verona in October, learning about prostate cancer? Comprehensive multidisciplinary programme aimed at oncologists, urologists, radiologists and anyone else involved in treated prostate cancer. Spread the word!
May 21, 2025 at 4:12 PM
What could be better than 5 days in Verona in October, learning about prostate cancer? Comprehensive multidisciplinary programme aimed at oncologists, urologists, radiologists and anyone else involved in treated prostate cancer. Spread the word!
Reposted by Danny Vesprini
Exciting data presented in ESTRO 2025 plenary: 5 fraction adjuvant breast RT (26 Gy) at least as good (and possibly better?) than 15 fractions @icr.ac.uk #ESTRO2025
May 3, 2025 at 8:42 AM
Exciting data presented in ESTRO 2025 plenary: 5 fraction adjuvant breast RT (26 Gy) at least as good (and possibly better?) than 15 fractions @icr.ac.uk #ESTRO2025
Reposted by Danny Vesprini
Want to learn more about prostate radiotherapy contouring? Register for the ESTRO prostate contouring course- two evening sessions with me and @dannyvesprini.bsky.social More info here www.estro.org/Courses/2025...
Falcon Workshop on Prostate SBRT
www.estro.org
February 20, 2025 at 5:39 PM
Want to learn more about prostate radiotherapy contouring? Register for the ESTRO prostate contouring course- two evening sessions with me and @dannyvesprini.bsky.social More info here www.estro.org/Courses/2025...
Reposted by Danny Vesprini
Ever wondered if urethral dose explained the differential GU toxicity by platform in PACE-B? It appears not- credit to Dr Ragu Ratnakumaran @ijrobp.bsky.social
eur01.safelinks.protection.outlook.com?url=https%3A...
eur01.safelinks.protection.outlook.com?url=https%3A...
ScienceDirect.com | Science, health and medical journals, full text articles and books.
eur01.safelinks.protection.outlook.com
January 24, 2025 at 4:00 PM
Ever wondered if urethral dose explained the differential GU toxicity by platform in PACE-B? It appears not- credit to Dr Ragu Ratnakumaran @ijrobp.bsky.social
eur01.safelinks.protection.outlook.com?url=https%3A...
eur01.safelinks.protection.outlook.com?url=https%3A...
Reposted by Danny Vesprini
ICYMI: *30* year outcomes from SPCG-4
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
November 23, 2024 at 3:04 AM
ICYMI: *30* year outcomes from SPCG-4
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
dx.doi.org/10.1056/NEJM...
RP vs. WW for clinically detected #prostatecancer reduces CSM 48% and *ACM* by 26%. NNT down to 6. Clear benefit to treatment of clinically detectable disease if (and only if) your pt has a very long life expectancy. #pcsm
First @bsky.app post!
Happy to share our recently published review on screening guidelines for people at risk of prostate cancer in the Oct issue of the Canadian Urological Association Journal/CUAJ
Led by #SunnybrookHSC genetic guru @justinlorentz.bsky.social
cuaj.ca/index.php/jo...
Happy to share our recently published review on screening guidelines for people at risk of prostate cancer in the Oct issue of the Canadian Urological Association Journal/CUAJ
Led by #SunnybrookHSC genetic guru @justinlorentz.bsky.social
cuaj.ca/index.php/jo...
Screening guidelines for people at increased risk for prostate cancer
| Canadian Urological Association Journal
cuaj.ca
November 20, 2024 at 6:40 PM
First @bsky.app post!
Happy to share our recently published review on screening guidelines for people at risk of prostate cancer in the Oct issue of the Canadian Urological Association Journal/CUAJ
Led by #SunnybrookHSC genetic guru @justinlorentz.bsky.social
cuaj.ca/index.php/jo...
Happy to share our recently published review on screening guidelines for people at risk of prostate cancer in the Oct issue of the Canadian Urological Association Journal/CUAJ
Led by #SunnybrookHSC genetic guru @justinlorentz.bsky.social
cuaj.ca/index.php/jo...